CR20250020A - N-(2-(3-ciano-2-azabiciclo[3.1.0]hexan-2-il)-2-oxoetil)-quinolina-4-carboxamidas - Google Patents

N-(2-(3-ciano-2-azabiciclo[3.1.0]hexan-2-il)-2-oxoetil)-quinolina-4-carboxamidas

Info

Publication number
CR20250020A
CR20250020A CR20250020A CR20250020A CR20250020A CR 20250020 A CR20250020 A CR 20250020A CR 20250020 A CR20250020 A CR 20250020A CR 20250020 A CR20250020 A CR 20250020A CR 20250020 A CR20250020 A CR 20250020A
Authority
CR
Costa Rica
Prior art keywords
hexan
carboxamides
oxoethyl
azabicyclo
quinoline
Prior art date
Application number
CR20250020A
Other languages
English (en)
Inventor
Gavin O'mahony
Jonas Brånalt
Anneli Nordqvist
Marianne Swanson
Maria Johansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20250020A publication Critical patent/CR20250020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos que tienen la estructura de la Fórmula (I): <img alt="" src="data:image/png;base64,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 (***)
CR20250020A 2022-06-21 2023-06-20 N-(2-(3-ciano-2-azabiciclo[3.1.0]hexan-2-il)-2-oxoetil)-quinolina-4-carboxamidas CR20250020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263366700P 2022-06-21 2022-06-21
PCT/EP2023/066560 WO2023247488A1 (en) 2022-06-21 2023-06-20 N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)- quinoline-4-carboxamides

Publications (1)

Publication Number Publication Date
CR20250020A true CR20250020A (es) 2025-05-26

Family

ID=87047759

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250020A CR20250020A (es) 2022-06-21 2023-06-20 N-(2-(3-ciano-2-azabiciclo[3.1.0]hexan-2-il)-2-oxoetil)-quinolina-4-carboxamidas

Country Status (19)

Country Link
US (1) US20230406840A1 (es)
EP (1) EP4543869A1 (es)
JP (1) JP2025525345A (es)
KR (1) KR20250044660A (es)
CN (1) CN119562947A (es)
AR (1) AR129669A1 (es)
AU (1) AU2023288735A1 (es)
CA (1) CA3260241A1 (es)
CL (1) CL2024003889A1 (es)
CO (1) CO2025000307A2 (es)
CR (1) CR20250020A (es)
DO (1) DOP2024000266A (es)
IL (1) IL317723A (es)
MA (1) MA71235A (es)
MX (1) MX2024015642A (es)
PE (1) PE20251704A1 (es)
TW (1) TW202417422A (es)
UY (1) UY40322A (es)
WO (1) WO2023247488A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
US11504364B2 (en) * 2018-12-21 2022-11-22 Praxis Biotech LLC Inhibitors of fibroblast activation protein

Also Published As

Publication number Publication date
EP4543869A1 (en) 2025-04-30
WO2023247488A1 (en) 2023-12-28
JP2025525345A (ja) 2025-08-05
PE20251704A1 (es) 2025-07-02
MA71235A (fr) 2025-04-30
UY40322A (es) 2023-12-15
AU2023288735A1 (en) 2025-02-13
MX2024015642A (es) 2025-02-10
US20230406840A1 (en) 2023-12-21
CO2025000307A2 (es) 2025-01-23
IL317723A (en) 2025-02-01
DOP2024000266A (es) 2025-07-15
CL2024003889A1 (es) 2025-02-07
KR20250044660A (ko) 2025-04-01
TW202417422A (zh) 2024-05-01
CN119562947A (zh) 2025-03-04
AR129669A1 (es) 2024-09-18
CA3260241A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
BRPI0400860A (pt) Sistema e método para facilitar perfilamento de aplicações
Ramírez‐Rico et al. Acanthamoeba castellanii proteases are capable of degrading iron‐binding proteins as a possible mechanism of pathogenicity
TR200002224T2 (tr) Matris-bozucu metalloproteinasları inhibe eden sülfonilamino türevleri.
BR112019008676A2 (pt) sistema para gerar um mapa de rendimento, método para gerar um mapa de rendimento, elemento de programa de computador e meio elegível
DK2040606T3 (da) Forbedringer af eller vedørende scanningsftalmoskoper
JP1790168S (ja) 情報表示用画像
BR112022019869A2 (pt) Modo de relatório de medição condicional para posicionamento
CR20250020A (es) N-(2-(3-ciano-2-azabiciclo[3.1.0]hexan-2-il)-2-oxoetil)-quinolina-4-carboxamidas
CY1107473T1 (el) Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις
CR20250018A (es) Derivados novedosos de indol sulfonamida 7 sustituidos
Pérez-Vargas et al. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants
CR20250058A (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
AU2020235128A8 (en) Transparent or semitransparent inverse microlatices of polyacrylamide as oil emulsion drift reducing agent
FR3082841B1 (fr) Stabilisation du trifluoroiodomethane
EP4250004A4 (en) DISPLAY SYSTEM
EP4118089C0 (en) Crystallization of 2&#39;-fl
PH12021550386A1 (en) Polythiol composition
JP1804500S (ja) 情報表示用画像
BR112021016585A2 (pt) Dispositivo de imagem de ultrassom
Barrett et al. α1‐antitrypsin and C‐reactive protein levels in tear fluid after continuous contact lens wear
BR112021019566A2 (pt) Novo composto e uso do mesmo
MX2022005440A (es) Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2).
Zeng et al. Corrigendum to “Evaluating a commercially available in-duct bipolar ionization device for pollutant removal and potential byproduct formation”[Build. Environ, Volume 195, May 2021, 107750]
Gonçalves et al. Web accessibility–From the evaluation and analysis to the implementation–The anoGov/PEPPOL case
KR20210107395A (ko) 병원정보제공시스템